Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new... see more

Recent & Breaking News (NDAQ:BLUE)

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)

Business Wire September 22, 2020

bluebird bio Announces September Investor Events

Business Wire September 2, 2020

bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel (eli-cel, Lenti-D(TM)) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD), Including Updated Long-Term Data, at the 46th Annual Meeting of the EBMT

Business Wire August 29, 2020

bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D(TM)) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting

Business Wire August 17, 2020

bluebird bio Appoints Denice Torres to Board of Directors

Business Wire August 11, 2020

bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress

Business Wire August 5, 2020

bluebird bio Announces August Investor Event

Business Wire July 31, 2020

Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma

Business Wire July 29, 2020

New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio's LentiGlobin(TM) Gene Therapy for Sickle Cell Disease at 25th EHA Congress

Business Wire June 12, 2020

Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel (LentiGlobin(TM) for ?-thalassemia) Gene Therapy Presented at EHA Congress

Business Wire June 12, 2020

bluebird bio Announces That Its 2020 Annual Meeting of Stockholders Will Be Held in Virtual Format

Business Wire June 3, 2020

bluebird bio Announces Live Webcast of EHA Data Review and June Investor Events

Business Wire May 28, 2020

bluebird bio Announces Pricing of Public Offering of Common Stock

Business Wire May 18, 2020

bluebird bio Announces Proposed Public Offering of Common Stock

Business Wire May 18, 2020

bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual Congress

Business Wire May 14, 2020

Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20

Business Wire May 13, 2020

Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma

Business Wire May 13, 2020

bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement

Business Wire May 11, 2020

bluebird bio Provides Operational and Business Update and Reports First Quarter 2020 Financial Results

Business Wire May 11, 2020

bluebird bio to Present Updated Results From Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma During ASCO20 Virtual Scientific Program

Business Wire May 8, 2020